(Q43542810)

English

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy

scientific article published on 29 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1 reference

based on heuristic

inferred from title

author name string

Matthew D Galsky

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Erin Moshier

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Susan Krege

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Chia-Chi Lin

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Noah Hahn

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Thorsten Ecke

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Guru Sonpavde

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

James Godbold

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

William K Oh

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Aristotle Bamias

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

29 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

119

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

3012-3019

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

How to build and interpret a nomogram for cancer prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Evaluating the yield of medical tests

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Distinct patterns of microsatellite instability are seen in tumours of the urinary tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

21 January 2018

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

7 January 2021

based on heuristic

inferred from DOI database lookup

Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukocytosis in non hematological malignancies--a possible tumor-associated marker

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28146

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28146

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43542810&oldid=2098207049"